Key Takeaways

• Combination products require complex sterile packaging that prevents chemical interaction and supports drug stability.
• OEMs face higher scrutiny for sterile barrier integrity, traceability, and ISO 11607 validation.
• Delaying packaging decisions can lead to rework, missed deadlines, and submission risk.
• Outsourcing sterile packaging works best when integrated early with the right partner.
• Millstone helps OEMs gain an advantage by streamlining sterile packaging, testing, and validation in one expert-led workflow.

New Rules for Sterile Packaging in Combination Products

The medical device industry is no stranger to complexity. But in recent years, few product categories have introduced more packaging complications and regulatory consequences than combination products. These complex medical devices, which merge a medical device with a drug or biologic, sit at the intersection of multiple regulatory frameworks, making their sterile packaging requirements some of the most stringent and misunderstood in the industry.
Yet with the right expertise, packaging doesn’t have to be a barrier. It can be a strategic accelerator. For medical device original equipment manufacturers (OEMs) developing combination products, partnering with a packaging provider who understands the intricacies of combination product classification, sterile packaging, shelf life, and compliance expectations can mean the difference between costly delays and confident submission.

The Rise of Combination Products

Over the past decade, the medical device landscape has evolved. More OEMs are introducing products that integrate device functionality with drug or biologic delivery, aiming to improve patient outcomes and enable point-of-care treatment.

These combination products, ranging from drug-eluting stents to prefilled injectors and antimicrobial dressings, introduce entirely new risk profiles, requiring a fresh set of sterile packaging considerations.

The FDA defines a combination product as a product composed of any combination of a drug, device, and/or biological product. That classification triggers compliance not only with device regulations (like ISO 11607 for packaging of terminally sterilized devices), but also with cGMP (Current Good Manufacturing Practice) requirements for pharmaceuticals under 21 CFR Parts 210 and 211.

As a result, OEMs must navigate:

• Dual regulatory oversight from the FDA’s Center for Devices and Radiological Health (CDRH) and Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER)
• More rigorous sterile packaging validation protocols
• Expanded documentation, testing, and traceability requirements

This convergence of regulatory expectations makes sterile packaging one of the most critical elements of combination product success and one of the most overlooked.

Why Sterile Packaging for Combination Products Is So Complex

For standard medical devices, sterile packaging must maintain sterility, protect product integrity, and support aseptic presentation. For combination products, those requirements expand.
Packaging for combination products must also:

• Prevent chemical interaction between the device and the drug or biologic
• Maintain the stability of both components over the shelf life.
• Withstand sterilization methods without compromising safety or efficacy.
• Comply with both ISO 11607 and pharmaceutical cGMP standards.

Sterile packaging for combination products must serve as both a physical barrier and a chemical safeguard. That’s a tall order, especially when internal teams may not have the resources or expertise to execute packaging, assembly, and validation to the required standard.

• Here’s what OEMs face:
  Compatibility challenges: Materials must be compatible with both the device and the drug, including adhesives, inks, and barrier films
• Testing burdens: OEMs must consider sterile barrier integrity, distribution simulation, accelerated aging, drug stability, and extractables and leachables.
• Labeling complexity: Teams must reconcile UDI compliance, dosage instructions, and pharmaceutical labeling rules.

Millstone Medical has seen many OEMs arrive late in the process with “nearly final” sterile packaging systems, only to discover chemical incompatibility or validation gaps that stall launch. That’s why early engagement with packaging experts is critical.

The Role of Sterile Packaging for Combination Products in Regulatory Approval

The FDA has clarified its expectations through guidance documents like “Current Good Manufacturing Practice Requirements for Combination Products” and frequent inspection focus areas. Key areas of emphasis include:

• Design Controls: OEMs must validate sterile packaging for combination products within a design control framework that includes user needs, risk management, and traceability.
• Sterility Assurance: For sterile combination products, ISO 11607 still applies, but manufacturers must also demonstrate that the drug or biologic remains stable throughout the sterilization process.
• Stability Testing: Teams must justify shelf life using accelerated aging or real-time data, including assessments of drug potency and packaging integrity.
• cGMP Integration: Combination product manufacturers must align their quality systems with both 21 CFR Part 820 (device) and Parts 210/211 (pharma) requirements, including procedures for cleanliness, labeling, sampling, and documentation.
• Documentation and Traceability: Every component in the sterile packaging system, including trays, lids, pouches, seals, and labels, must be traceable and validated.

OEMs must make sterile packaging decisions with regulatory scrutiny in mind. If the team can’t justify the rationale with data, regulators will not accept it.

Designing Sterile Packaging for Dual-Modality Devices

Today’s regulatory expectations demand more than packaging that simply protects. OEMs must now deliver sterile packaging systems that maintain sterility, ensure chemical compatibility, meet dual labeling regulations, and hold up under rigorous validation. For many, the challenge is significant, especially when internal teams are already stretched thin.

Even the most experienced OEMs may lack:

• Cleanroom space rated for combination product assembly
• Access to ISO 17025-accredited laboratories for testing
• Expertise in both sterile packaging for medical devices and pharmaceutical compliance
• Bandwidth to manage evolving FDA and ISO documentation requirements

That’s why many turn to outsourcing. But this path introduces its challenges.

Not all outsourcing is equal. When a sterile packaging partner lacks regulatory fluency or fails to align with internal development timelines, delays mount, and rework becomes inevitable. Outsourcing done too late in the process or done poorly can compromise the very compliance it aims to support.

For outsourcing to work, it must be strategic, early, and integrated.

The right partner becomes an extension of your team, advising on materials, sealing methods, labeling strategy, and validation protocols from the start. This level of support not only accelerates timelines but also ensures the sterile packaging system meets FDA, ISO, and EU MDR expectations without unnecessary trial and error.

Engage your packaging partner when:

• Reviewing concept and device design
• Selecting sterilization methods
• Finalizing materials for trays, lids, seals, or labels
• Drafting validation protocols or stability test plans
• Developing your regulatory submission strategy

A strategic partnership doesn’t just solve capacity problems. It prevents costly mistakes, strengthens your regulatory position, and moves your launch timeline forward.

Your Tier 1 Partner for Combination Product Packaging

Millstone Medical Outsourcing offers an integrated approach explicitly built to support the complexity of sterile packaging for combination products. With ISO 7 cleanrooms, in-house ISO 17025-accredited testing labs, and pharmaceutical-grade SOPs, Millstone simplifies the path to market.

Here’s how:

• Integrated Packaging and Testing: Millstone executes sterile packaging and validation in a unified workflow, reducing handoffs, timelines, and risk.
• Pharma-Grade Cleanrooms: Operations comply with cGMP principles to meet the elevated sterility and documentation expectations of drug-device products.
• Chemical Compatibility and Biocompatibility Testing: Through ISO 10993 evaluations and extractables/leachables assessments, Millstone helps OEMs select packaging materials that won’t compromise drug efficacy.
• Shelf Life and Stability Studies: Accelerated aging, real-time studies, and stability protocols ensure that sterile packaging supports the entire shelf life of the product.
• Labeling and Serialization: Millstone manages complex combination product labeling, integrating UDI and pharmaceutical guidance into one compliant system.

Millstone’s regulatory experts support every step with clear interpretation and guidance. Our team develops the protocol, executes it with precision, defends it with data, and continuously improves it.

Turn Combination Product Packaging Into Your Launch Advantage

Combination product success hinges on integration across sterile packaging, testing, and compliance systems. When these elements operate in silos, OEMs face costly rework, missed deadlines, and regulatory pushback. Millstone eliminates that fragmentation by delivering all sterile packaging, assembly, and validation services in one streamlined, expert-driven workflow.

With Millstone, OEMs gain:

• Confidence in Dual Compliance: Millstone executes sterile packaging solutions that meet the highest standards across drug and device regulations, including FDA, ISO, and EU MDR. Our deep regulatory fluency ensures each solution is not only compliant but confidently defensible.
• Accelerated Time to Market: With access to pre-validated tray and pouch systems, integrated testing, and established protocols, OEMs can move faster from development to submission with fewer iterations and surprises.
• Fewer Handoffs, Greater Accountability: By consolidating cleanroom assembly, biocompatibility testing, labeling, and validation under one roof, Millstone reduces the risk of miscommunication, delays, and nonconformities. One partner. One plan. One path forward.
• Strategic Guidance from Day One: Millstone’s team understands what regulators want to see and helps you build that into your sterile packaging system from the start. From material selection to test justification, we help OEMs anticipate and address issues before they become obstacles.

Packaging does not have to be the most challenging part of your combination product launch. With Millstone, packaging becomes your strategic advantage to accelerate readiness, strengthen compliance, and scale global success.